Ferro Corp. (FOE) said that Benjamin Schlater, who has served as Ferro’s Vice President, Corporate Development and Strategy since September 2015, has been named Vice President and Chief Financial Officer, succeeding Jeffrey Rutherford, who stepped down from the position on September 1.
James Barna, Ferro’s Corporate Controller, has been appointed to the additional role of Chief Accounting Officer of the Company.
Lori Saviers, who was Ferro’s Chief Procurement Officer, has been named Vice President, Sourcing and Global Supply Chain. In addition, Sandy Frydryk has been named Director, Corporate Development and Integration.
Rutherford is expected to remain with the Company as an advisor to Schlater through the end of 2016 to ensure a smooth transition of responsibilities.
Schlater joined Ferro in September 2015. He has nearly 20 years of corporate finance experience. His experience includes serving as treasurer and head of corporate development, strategic and financial planning, and risk management at Veyance Technologies, a $2 billion global manufacturing company then owned by The Carlyle Group. Prior to Veyance, he was a managing director at FTI Consulting. Prior to that, he was a manager at PricewaterhouseCoopers in its corporate finance practice.
Source: RTT News
Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.
Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.
The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).
